A new phase 3 clinical trial published in the British Journal of Anaesthesia (Zhao et al., 2025) introduces adamgammadex, a novel γ-cyclodextrin-based compound, as a powerful alternative to sugammadex for reversing rocuronium-induced neuromuscular blockade. This breakthrough could reshape perioperative care by offering faster recovery times and an improved safety profile.

What is adamgammadex?

Adamgammadex is a chemically modified cyclodextrin that works similarly to sugammadex—it encapsulates rocuronium molecules to reverse neuromuscular blockade. However, its structural modifications were designed to:

• Increase binding affinity to rocuronium
  
• Reduce the risk of hypersensitivity reactions
  
• Improve pharmacokinetics and clearance

Study design at a glance

• Type: Randomized, double-blind, controlled phase 3 trial
  
• Population: 402 adult patients undergoing elective surgery under general anesthesia
  
• Intervention: Rocuronium 0.6 mg/kg for neuromuscular block, followed by either:
  
  • Adamgammadex 2 mg/kg (n = 302)
    
  • Sugammadex 2 mg/kg (n = 100)
• Primary endpoint: Time to recovery of TOF ratio ≥0.9
• Secondary endpoints: TOF ≥0.8 and ≥1.0, safety outcomes

Results: rapid and reliable recovery

Key efficacy findings

• Time to TOF ratio ≥0.9:
  
  • Adamgammadex: 1.49 ± 0.60 min
    
  • Sugammadex: 1.63 ± 0.78 min
    
  • ➤ Adamgammadex was non-inferior and slightly faster
    
• Time to TOF ≥1.0:
  
  • Adamgammadex: 2.00 ± 0.67 min
    
  • Sugammadex: 2.14 ± 0.89 min

Interpretation

• Adamgammadex achieves rapid, consistent recovery from moderate neuromuscular block
  
• Statistically non-inferior and numerically faster than sugammadex

Safety profile: a major strength

Adverse events:

• Overall adverse event rates:
  
  • Adamgammadex: 15.2%
    
  • Sugammadex: 17.0%
    
• Injection site pain was the most common event
  
• No hypersensitivity reactions were observed with adamgammadex
  
• Bradycardia, nausea, and vomiting occurred at similar low frequencies in both groups

Why this matters:

• Sugammadex, while effective, has been associated with anaphylaxis and hypersensitivity, prompting the need for safer alternatives
  
• Adamgammadex may offer a lower risk of immune-mediated side effects

Comparing adamgammadex and sugammadex

Clinical implications

If approved, adamgammadex could be a game-changer in anesthesia practice by:

• Offering faster recovery
  
• Reducing perioperative complications
  
• Avoiding hypersensitivity reactions associated with sugammadex
  
• Serving as an important alternative in patients with known allergy risks

Final thoughts

This trial positions adamgammadex as a highly effective and potentially safer option for rapid neuromuscular block reversal. As the anesthesia community seeks to enhance safety and efficiency, adamgammadex may soon become a cornerstone of modern perioperative care.

For more detailed information, refer to the full article in BJA.

Zhao Y et al. Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. Br J Anaesth. 2025;135:331-339.

Get this and more in the AA App

This content is also available in the NYSORA Anesthesia Assistant App — your smart, expert-reviewed tool for:

• Point-of-care decisions: Instant, evidence-based guidance
• AI support (MAIA): Tools like DoseCalc and Case Manager
• Weekly updates: Protocols, tips, and exam-ready knowledge

Built on science, reviewed by experts — smarter (and safer) than a web search.

Download the AA App now to put trusted anesthesia guidance in your pocket.